Guided Therapeutics Answers FDA Questions for LuViva™ Advanced Cervical Scan PMA

Guided Therapeutics, Inc. GTHP today announced that it has answered all key questions from the U.S. Food and Drug Administration (FDA) regarding the company's premarket approval application for the LuViva™ Advanced Cervical Scan. “We are pleased to provide the FDA with the additional information the agency requested and within the time period required to maintain the PMA application under active review,” said Mark L. Faupel, Ph.D., President and CEO of Guided Therapeutics. “The FDA will review our submission, we hope move forward with the PMA process and schedule a panel meeting date, although the agency has the option to ask for additional information.”